WO2016064959A1 - Implant oculaire à deux couches comprenant un inhibiteur de tyrosine kinase - Google Patents

Implant oculaire à deux couches comprenant un inhibiteur de tyrosine kinase Download PDF

Info

Publication number
WO2016064959A1
WO2016064959A1 PCT/US2015/056579 US2015056579W WO2016064959A1 WO 2016064959 A1 WO2016064959 A1 WO 2016064959A1 US 2015056579 W US2015056579 W US 2015056579W WO 2016064959 A1 WO2016064959 A1 WO 2016064959A1
Authority
WO
WIPO (PCT)
Prior art keywords
implant
agents
eye
layer
ocular
Prior art date
Application number
PCT/US2015/056579
Other languages
English (en)
Inventor
Karl CSAKY
Original Assignee
Odin Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odin Biotech filed Critical Odin Biotech
Publication of WO2016064959A1 publication Critical patent/WO2016064959A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts

Abstract

La présente invention concerne généralement des thérapies locales pour l'oeil et, plus particulièrement, des dispositifs d'implant oculaire à libération contrôlée formés, comprenant des procédés de fabrication et d'utilisation de tels dispositifs, pour l'administration d'agents thérapeutiques à l'oeil. Un implant oculaire à deux couches moulé comprend un agent thérapeutique pour le traitement ou la prévention d'un trouble oculaire. L'implant comprend une couche de polymère et une couche adhésive de silicone avec un agent thérapeutique dispersé dans celle-ci et assemblée à la couche de polymère. Cet implant est destiné à être placé dans l'espace sous-ténonien de l'oeil et permet une libération prolongée de l'agent thérapeutique tel que des inhibiteurs de tyrosine kinase pendant le traitement ou la prévention du trouble de l'oeil.
PCT/US2015/056579 2014-10-21 2015-10-21 Implant oculaire à deux couches comprenant un inhibiteur de tyrosine kinase WO2016064959A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066466P 2014-10-21 2014-10-21
US62/066,466 2014-10-21

Publications (1)

Publication Number Publication Date
WO2016064959A1 true WO2016064959A1 (fr) 2016-04-28

Family

ID=55761462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/056579 WO2016064959A1 (fr) 2014-10-21 2015-10-21 Implant oculaire à deux couches comprenant un inhibiteur de tyrosine kinase

Country Status (1)

Country Link
WO (1) WO2016064959A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108578059A (zh) * 2018-05-30 2018-09-28 清华大学深圳研究生院 一种可控药物缓释的角膜接触镜
CN111757888A (zh) * 2017-09-07 2020-10-09 深圳信立泰药业股份有限公司 多西紫杉醇共缀物在制备预防或治疗各种免疫疾病的药物中的应用
US11040019B2 (en) 2016-08-19 2021-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
WO2023028600A1 (fr) * 2021-08-26 2023-03-02 Vinci Pharmaceuticals, Inc. Dispositif oculaire et procédés
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272777A1 (en) * 2001-03-15 2010-10-28 The Government Of The United States Of America, As Represented By The Secretary, Ocular therapeutic agent delivery devices and methdos for making and using such devices
US20130210877A1 (en) * 2010-08-27 2013-08-15 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US20130236525A1 (en) * 2004-04-30 2013-09-12 Allergan, Inc. Sustained release intraocular implants and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272777A1 (en) * 2001-03-15 2010-10-28 The Government Of The United States Of America, As Represented By The Secretary, Ocular therapeutic agent delivery devices and methdos for making and using such devices
US20130236525A1 (en) * 2004-04-30 2013-09-12 Allergan, Inc. Sustained release intraocular implants and related methods
US20130210877A1 (en) * 2010-08-27 2013-08-15 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040019B2 (en) 2016-08-19 2021-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
CN111757888A (zh) * 2017-09-07 2020-10-09 深圳信立泰药业股份有限公司 多西紫杉醇共缀物在制备预防或治疗各种免疫疾病的药物中的应用
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US11951215B2 (en) 2018-05-24 2024-04-09 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
CN108578059A (zh) * 2018-05-30 2018-09-28 清华大学深圳研究生院 一种可控药物缓释的角膜接触镜
WO2023028600A1 (fr) * 2021-08-26 2023-03-02 Vinci Pharmaceuticals, Inc. Dispositif oculaire et procédés

Similar Documents

Publication Publication Date Title
US10881609B2 (en) Methods for treating eye disorders using ocular implants
AU2015230797B2 (en) Drug eluting ocular implant
US7658364B2 (en) Ocular therapeutic agent delivery devices and methods for making and using such devices
US9999595B2 (en) Eye device
WO2016064959A1 (fr) Implant oculaire à deux couches comprenant un inhibiteur de tyrosine kinase
US20100209477A1 (en) Sustained release delivery of one or more agents
AU2022334744A1 (en) Ocular device and methods
CN111358751B (zh) 眼用药物组合物、眼用药盒及其医药用途
WO2021092470A1 (fr) Composés et implants pour le traitement de troubles oculaires
WO2016178900A1 (fr) Implant oculaire pour l'administration de dérivé pyridine-carboxamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15853186

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15853186

Country of ref document: EP

Kind code of ref document: A1